Published in Gene Therapy Weekly, October 5th, 2006
"Choroidal neovascularization (CNV) is the leading cause of blindness in AMD. Several lines of evidence implicate increased levels of vascular endothelial growth factor (VEGF) in retinal pigment epithelium (RPE) from patients with AMD," scientists in the United States report.
"Current approaches to attenuate VEGF or its receptors, including the use of small interfering (si) RNA, show significant promise but still have limited efficacy and require repeat administrations, using procedures associated with multiple complications. The goal of this study was to develop...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly